Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study

Schizophrenia Research

Volumn 147, Issue 1, 2013, Pages 132-139

  Wobrock, T ^a,b   Falkai, P ^c   Schneider Axmann, T ^c   Hasan, A ^c   Galderisi, S ^d   Davidson, M ^e   Kahn, R S ^f   Derks, E M ^f   Boter, H ^g   Rybakowski, J K ^h   Libiger, J ⁱ   Dollfus, S ^j   Lopez Ibor J J ^k   Peuskens, J ^l   Hranov, L G ^m   Gaebel, W ⁿ   Fleischhacker, W W ^o  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Darmstadt Dieburg Clinics   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e SHEBA MEDICAL CENTER   (Israel)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

ⁱ UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^j CAEN UNIVERSITY HOSPITAL   (France)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

ⁿ HEINRICH HEINE UNIVERSITY   (Germany)

^o INNSBRUCK MEDICAL UNIVERSITY   (Austria)

more..

Author keywords

Cognitive function; Dual diagnosis; First episode schizophrenia; Substance abuse

Indexed keywords

AMISULPRIDE; AMPHETAMINE; CHLORPROMAZINE; COCAINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

ADULT; ALCOHOL USE DISORDER; ARTICLE; AUSTRIA; BELGIUM; BULGARIA; CANNABIS ADDICTION; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; CZECH REPUBLIC; DSM-IV; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NETHERLANDS; NEUROPSYCHOLOGICAL TEST; POLAND; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMOTOR PERFORMANCE; REY AUDITORY VERBAL LEARNING TEST; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SPAIN; SUBSTANCE ABUSE; SWITZERLAND;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ANTISOCIAL PERSONALITY DISORDER; CHLORPROMAZINE; COGNITION DISORDERS; EUROPE; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; VERBAL LEARNING; YOUNG ADULT;

EID: 84877102246     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.03.001     Document Type: Article

References (46)

1. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 1993, (22):39-44.
2. Beatty W.W., Katzung V.M., Moreland V.J., Nixon S.J. Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend. 1995, 37(3):247-253.
3. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 2009, 35(2):383-402.
4. Buhler B., Hambrecht M., Loffler W., an der Heiden W., Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 2002, 54(3):243-251.
5. Cantwell R., Brewin J., Glazebrook C., Dalkin T., Fox R., Medley I., Harrison G. Prevalence of substance misuse in first-episode psychosis. Br. J. Psychiatry 1999, 174:150-153.
6. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249(1):45-49.
7. Cleghorn J.M., Kaplan R.D., Szechtman B., Szechtman H., Brown G.M., Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J. Clin. Psychiatry 1991, 52(1):26-30.
8. Costa L.D., Vaughan H.G., Levita E., Farber N. Purdue Pegboard as a predictor of the presence and laterality of cerebral lesions. J. Consult. Psychol. 1963, 27:133-137.
9. Coulston C.M., Perdices M., Tennant C.C. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Aust. N. Z. J. Psychiatry 2007, 41(11):869-884.
10. Dixon L., Haas G., Weiden P.J., Sweeney J., Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 1991, 148(2):224-230.
11. Duke P.J., Pantelis C., McPhillips M.A., Barnes T.R. Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London. Br. J. Psychiatry 2001, 179:509-513.
12. Eckardt M.J., Stapleton J.M., Rawlings R.R., Davis E.Z., Grodin D.M. Neuropsychological functioning in detoxified alcoholics between 18 and 35years of age. Am. J. Psychiatry 1995, 152(1):53-59.
13. Galderisi S., Davidson M., Kahn R.S., Mucci A., Boter H., Gheorghe M.D., Rybakowski J.K., Libiger J., Dollfus S., Lopez-Ibor J.J., Peuskens J., Hranov L.G., Fleischhacker W.W. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophr. Res. 2009, 115(2-3):104-114.
14. Gerlach J., Korsgaard S., Clemmesen P., Lauersen A.M., Magelund G., Noring U., Povlsen U.J., Bech P., Casey D.E. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 1993, 87(4):244-252.
15. Graham H.L., Maslin J., Copello A., Birchwood M., Mueser K., McGovern D., Georgiou G. Drug and alcohol problems amongst individuals with severe mental health problems in an inner city area of the UK. Soc. Psychiatry Psychiatr. Epidemiol. 2001, 36(9):448-455.
16. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153(3):321-330.
17. Guy W B.R. CGI: Clinical Global Impressions 1976, National Institute of Mental Health.
18. Hambrecht M., Hafner H. Substance abuse and the onset of schizophrenia. Biol. Psychiatry 1996, 40(11):1155-1163.
19. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
20. Jackson C.T., Fein D., Essock S.M., Mueser K.T. The effects of cognitive impairment and substance abuse on psychiatric hospitalizations. Community Ment. Health J. 2001, 37(4):303-312.
21. Jensen J., Nilsson L.L., Levander S. Neurocognitive and psychopathological correlates of self-monitoring ability in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254(5):312-317.
22. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
24. Kovasznay B., Fleischer J., Tanenberg-Karant M., Jandorf L., Miller A.D., Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr. Bull. 1997, 23(2):195-201.
25. Leeson V.C., Harrison I., Ron M.A., Barnes T.R., Joyce E.M. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr. Bull. 2012, 38(4):873-880.
26. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry 1994, 51(4):273-279.
27. Liraud F., Verdoux H. Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. Encephale 2002, 28(2):160-168.
28. Meijer J.H., Dekker N., Koeter M.W., Quee P.J., van Beveren N.J., Meijer C.J. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol. Med. 2012, 42(4):705-716.
29. Mueser K.T., Yarnold P.R., Levinson D.F., Singh H., Bellack A.S., Kee K., Morrison R.L., Yadalam K.G. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr. Bull. 1990, 16(1):31-56.
30. Nixon S.J., Hallford H.G., Tivis R.D. Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. Psychiatry Res. 1996, 64(1):35-45.
31. Peer J., Bennett M.E., Bellack A.S. Neurocognitive characteristics of individuals with schizophrenia and cocaine dependence: comparison of currently dependent and remitted groups. J. Nerv. Ment. Dis. 2009, 197(8):631-634.
32. Pope H.G., Gruber A.J., Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995, 38(1):25-34.
33. Rabin R.A., Zakzanis K.K., George T.P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr. Res. 2011, 128(1-3):111-116.
34. Rabinowitz J., Bromet E.J., Lavelle J., Carlson G., Kovasznay B., Schwartz J.E. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol. Med. 1998, 28(6):1411-1419.
35. Reitan R.M., Wolfson D. The Halstead - Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation 1993, Neuropsychology Press, Tucson. 2nd ed.
36. Rey A. L'Examen clinique en psychologie 1964, Presses Universitaires de France, Paris.
37. Rodriguez-Jimenez R., Bagney A., Martinez-Gras I., Ponce G., Sanchez-Morla E.M., Aragues M., Rubio G., Jimenez-Arriero M.A., Santos J.L., Palomo T. Executive function in schizophrenia: influence of substance use disorder history. Schizophr. Res. 2010, 118(1-3):34-40.
38. Rodriguez-Sanchez J.M., Ayesa-Arriola R., Mata I., Moreno-Calle T., Perez-Iglesias R., Gonzalez-Blanch C., Perianez J.A., Vazquez-Barquero J.L., Crespo-Facorro B. Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophr. Res. 2010, 124(1-3):142-151.
39. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. (quiz 34-57).
40. Soyka M., Albus M., Immler B., Kathmann N., Hippius H. Psychopathology in dual diagnosis and non-addicted schizophrenics - are there differences?. Eur. Arch. Psychiatry Clin. Neurosci. 2001, 251(5):232-238.
41. Torrey E.F. Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr. Res. 2002, 58(2-3):101-115.
42. Veen N.D., Selten J.P., van der Tweel I., Feller W.G., Hoek H.W., Kahn R.S. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry 2004, 161(3):501-506.
43. Wechsler D. Wechsler Adult Intelligence Scale 1997, Psychological Corporation, San Antonio. 3rd ed.
44. Wobrock T., Sittinger H., Behrendt B., D'Amelio R., Falkai P., Caspari D. Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 257(4):203-210.
45. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
46. Yucel M., Bora E., Lubman D.I., Solowij N., Brewer W.J., Cotton S.M., Conus P., Takagi M.J., Fornito A., Wood S.J., McGorry P.D., Pantelis C. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr. Bull. 2012, 38(2):316-330.